RxDoctor Payments Data

Sam Giovannucci, MD

Internal Medicine · Grand Rapids, MINPI 1164478509

Payments from drug & device makers

$4,785in general payments, 2019–2025

Across 272 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$799
  • AstraZeneca$392
  • GSK$369
  • Boehringer Ingelheim$337
  • Novartis$255
  • Amgen$232
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$4,67998%
  • Education$1062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,785 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$22,769
Medicare patients
90
Services billed
2,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol38$58,813
EliquisApixaban44$45,307
JardianceEmpagliflozin34$44,369
TrulicityDulaglutide35$39,661
XareltoRivaroxaban23$27,384
JanuviaSitagliptin Phosphate22$25,430
MyrbetriqMirabegron23$20,696
MounjaroTirzepatide19$19,346
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$16,779
Aimovig AutoinjectorErenumab-Aooe13$9,284
Colesevelam Hcl34$6,834
AmbienZolpidem Tartrate12$6,764
Ezetimibe229$6,548
Rivastigmine35$6,338
Estradiol (Twice Weekly)Estradiol37$4,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$392$63,45556 claims
Lilly USA, LLCTrulicity, Mounjaro$192$59,00754 claims
PfizerEliquis$199$45,30744 claims
Boehringer IngelheimJardiance$337$44,36934 claims
Johnson & JohnsonXarelto$60$27,38423 claims
Astellas Pharma US IncMyrbetriq$124$20,69623 claims
GSKTrelegy Ellipta$369$16,77927 claims
Sanofi-aventis U.S. LLCAmbien$19$6,76412 claims
AbbVieSynthroid$205$1,32319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →